Dr. Rachel Bedard

And that's interesting because you really can't attribute that impact to weight loss.

Right, exactly.

Other than maybe there's some psychological impact, et cetera, et cetera.

But what we're sort of interested in is it's revealed that there are GLP-1 receptors in places where I think we didn't totally recognize they were there, didn't fully recognize their presence.

potential role in things that we weren't thinking about.

So there are GLP-1 receptors in like the dopamine reward circuitry in your brain.

And one sort of hypothesis around the addiction stuff or the sort of strongest hypothesis is that GLP-1 agonist binding there is interrupting reward circuitry pathway stuff in a way that for people who have strong reward pathways built around addictive behaviors, like it interrupts that.

I think it's the first.

I think that one of the things that's really interesting about the diverse array of effects that the GLP-1 drugs seem to have is that it's suggestive of the fact that obesity, which people who study obesity have long asserted, is a pathological condition that has consequences way beyond obesity.

just being overweight and moving around the world in a bigger body.

Having a lot of excess fat tissue on your body changes all sorts of hormone signaling and homeostasis mechanisms in your body.

So losing that adipose tissue, that fat tissue, makes a huge difference in changing how your body self-regulates.

And that seems to improve a whole bunch of things that we maybe didn't totally anticipate.

There's this sort of hand-wavy thing that the GLP-1s decrease inflammation, which is true.

We sort of do know that, that they decrease inflammatory markers in the body.

And just seeing all the different ways in which decreasing inflammation seems to help people is really fascinating.

A million things that are like question-marky things that look good.

Like I should just list some of them because it's so exciting.

Cancer prevention.

So we know this is another one where like,